Literature DB >> 33449974

Association of the erythropoiesis-stimulating agent resistance index and the geriatric nutritional risk index with cardiovascular mortality in maintenance hemodialysis patients.

Takahiro Yajima1, Kumiko Yajima2, Hiroshi Takahashi3.   

Abstract

OBJECTIVE: Hyporesponsiveness to erythropoiesis-stimulating agent (ESA) may be associated with protein-energy wasting. We investigated the relationship of the ESA resistance index (ERI) and the geriatric nutritional risk index (GNRI) for cardiovascular mortality in hemodialysis (HD) patients.
METHODS: A total of 180 maintenance HD patients were enrolled. The patients were stratified by the GNRI of 91.2, a previously reported cut-off value, and the ERI of 13.7 (IU/week/kg/g/dL), a cut-off value for predicting cardiovascular-specific mortality, and they were classified into four groups (group 1[G1]: higher GNRI and lower ERI, G2: higher GNRI and higher ERI, G3: lower GNRI and lower ERI, G4: lower GNRI and higher ERI).
RESULTS: The ERI was independently associated with the GNRI (β = -0.271, p = 0.0005). During a median follow-up of 4.6 years, higher ERI and lower GNRI were independently associated with cardiovascular mortality, respectively (adjusted hazard ratio [aHR], 3.10; 95% confidence interval [CI], 1.31-7.34, and aHR, 6.64; 95%CI, 2.60-16.93, respectively). The 7-year survival rates were 96.1%, 70.3%, 77.3%, and 50.1% in G1, G2, G3, and G4, respectively. The aHR values for G4 versus G1 were 12.63 (95%CI, 3.58-44.59). With regards to model discrimination, adding the GNRI alone, the ERI alone, and both to the traditional risk model significantly improved the net reclassification improvement by 0.421, 0.662, and 0.671, respectively. Similar results were obtained for all-cause mortality.
CONCLUSION: The ERI was independently associated with the GNRI, and could predict cardiovascular mortality in HD patients. Moreover, the combination of GNRI and ERI could improve the predictability for cardiovascular mortality.

Entities:  

Year:  2021        PMID: 33449974      PMCID: PMC7810304          DOI: 10.1371/journal.pone.0245625

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  34 in total

1.  Comparison of Nutritional Risk Scores for Predicting Mortality in Japanese Chronic Hemodialysis Patients.

Authors:  Hiroshi Takahashi; Keiko Inoue; Kazue Shimizu; Keiko Hiraga; Erika Takahashi; Kaori Otaki; Taeko Yoshikawa; Kumiko Furuta; Chika Tokunaga; Tomoyo Sakakibara; Yasuhiko Ito
Journal:  J Ren Nutr       Date:  2017-02-20       Impact factor: 3.655

Review 2.  Association of Geriatric Nutritional Risk Index with Mortality in Hemodialysis Patients: A Meta-Analysis of Cohort Studies.

Authors:  Jiachuan Xiong; Min Wang; Ying Zhang; Ling Nie; Ting He; Yiqin Wang; Yunjian Huang; Bing Feng; Jingbo Zhang; Jinghong Zhao
Journal:  Kidney Blood Press Res       Date:  2018-12-14       Impact factor: 2.687

3.  Epoetin requirements predict mortality in hemodialysis patients.

Authors:  Yi Zhang; Mae Thamer; Kevin Stefanik; James Kaufman; Dennis J Cotter
Journal:  Am J Kidney Dis       Date:  2004-11       Impact factor: 8.860

4.  Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?

Authors:  Annamaria T Kausz; Craig Solid; Brian J G Pereira; Allan J Collins; Wendy St Peter
Journal:  Am J Kidney Dis       Date:  2005-01       Impact factor: 8.860

5.  Inflammation enhances cardiovascular risk and mortality in hemodialysis patients.

Authors:  J Zimmermann; S Herrlinger; A Pruy; T Metzger; C Wanner
Journal:  Kidney Int       Date:  1999-02       Impact factor: 10.612

Review 6.  Erythropoiesis stimulatory agent- resistant anemia in dialysis patients: review of causes and management.

Authors:  Mehmet Kanbay; Mark A Perazella; Benan Kasapoglu; Mustafa Koroglu; Adrian Covic
Journal:  Blood Purif       Date:  2009-10-08       Impact factor: 2.614

7.  Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients.

Authors:  M Alan Brookhart; Janet K Freburger; Alan R Ellis; Lily Wang; Wolfgang C Winkelmayer; Abhijit V Kshirsagar
Journal:  J Am Soc Nephrol       Date:  2013-06-20       Impact factor: 10.121

8.  Impact of Annual Change in Geriatric Nutritional Risk Index on Mortality in Patients Undergoing Hemodialysis.

Authors:  Takahiro Yajima; Kumiko Yajima; Hiroshi Takahashi
Journal:  Nutrients       Date:  2020-10-29       Impact factor: 5.717

9.  Characterization of chronic and acute ESA hyporesponse: a retrospective cohort study of hemodialysis patients.

Authors:  Scott P Sibbel; Carol E Koro; Steven M Brunelli; Alexander R Cobitz
Journal:  BMC Nephrol       Date:  2015-08-18       Impact factor: 2.388

10.  The Impact of Abdominal Fat Levels on All-Cause Mortality Risk in Patients Undergoing Hemodialysis.

Authors:  Takahiro Yajima; Kumiko Yajima; Hiroshi Takahashi; Keigo Yasuda
Journal:  Nutrients       Date:  2018-04-12       Impact factor: 5.717

View more
  4 in total

1.  Prognostic value of geriatric nutritional risk index for aspiration pneumonia: a retrospective observational cohort study.

Authors:  Taisuke Araki; Yoshitaka Yamazaki; Norihiko Goto; Yuko Takahashi; Yuichi Ikuyama; Makoto Kosaka
Journal:  Aging Clin Exp Res       Date:  2021-08-11       Impact factor: 3.636

2.  Combined Evaluation of Geriatric Nutritional Risk Index and Modified Creatinine Index for Predicting Mortality in Patients on Hemodialysis.

Authors:  Takahiro Yajima; Kumiko Yajima; Maiko Arao
Journal:  Nutrients       Date:  2022-02-10       Impact factor: 5.717

3.  Psoas muscle index and psoas muscle density as predictors of mortality in patients undergoing hemodialysis.

Authors:  Takahiro Yajima; Maiko Arao; Kumiko Yajima
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

4.  Usefulness of computed tomography-measured psoas muscle thickness per height for predicting mortality in patients undergoing hemodialysis.

Authors:  Takahiro Yajima; Maiko Arao; Kumiko Yajima; Hiroshi Takahashi
Journal:  Sci Rep       Date:  2021-09-24       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.